These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36029715)

  • 1. Comparative effectiveness of preventive treatment with dimethyl fumarate-loaded solid lipid nanoparticles and oral dimethyl fumarate in a mouse model of multiple sclerosis.
    Bevilacqua Rolfsen Ferreira da Silva G; Pereira das Neves S; Roque Oliveira SC; Marques F; Gomes de Oliveira A; de Lima Leite F; Cerqueira JJ
    J Autoimmun; 2022 Oct; 132():102893. PubMed ID: 36029715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhalation of dimethyl fumarate-encapsulated solid lipid nanoparticles attenuate clinical signs of experimental autoimmune encephalomyelitis and pulmonary inflammatory dysfunction in mice.
    Pinto BF; Ribeiro LNB; da Silva GBRF; Freitas CS; Kraemer L; Oliveira FMS; Clímaco MC; Mourão FAG; Santos GSPD; Béla SR; Gurgel ILDS; Leite FL; de Oliveira AG; Vilela MRSDP; Oliveira-Lima OC; Soriani FM; Fujiwara RT; Birbrair A; Russo RC; Carvalho-Tavares J
    Clin Sci (Lond); 2022 Jan; 136(1):81-101. PubMed ID: 34904644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis.
    Traub J; Traffehn S; Ochs J; Häusser-Kinzel S; Stephan S; Scannevin R; Brück W; Metz I; Weber MS
    Brain Pathol; 2019 Sep; 29(5):640-657. PubMed ID: 30706542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
    Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L
    Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature.
    Dello Russo C; Scott KA; Pirmohamed M
    Pharmacol Ther; 2021 Mar; 219():107710. PubMed ID: 33091427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Explorative Assessment of Dimethyl Fumarate-Based Biocompatible Nanolipoidal Carriers for the Management of Multiple Sclerosis.
    Kumar P; Sharma G; Gupta V; Kaur R; Thakur K; Malik R; Kumar A; Kaushal N; Raza K
    ACS Chem Neurosci; 2018 May; 9(5):1152-1158. PubMed ID: 29357233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple rodent models and behavioral measures reveal unexpected responses to FTY720 and DMF in experimental autoimmune encephalomyelitis.
    de Bruin NM; Schmitz K; Schiffmann S; Tafferner N; Schmidt M; Jordan H; Häußler A; Tegeder I; Geisslinger G; Parnham MJ
    Behav Brain Res; 2016 Mar; 300():160-74. PubMed ID: 26692368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.
    Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J
    Mult Scler; 2019 Oct; 25(12):1682-1685. PubMed ID: 31208265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study.
    Marastoni D; Buriani A; Pisani AI; Crescenzo F; Zuco C; Fortinguerra S; Sorrenti V; Marenda B; Romualdi C; Magliozzi R; Monaco S; Calabrese M
    Front Immunol; 2019; 10():1666. PubMed ID: 31379857
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
    Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis.
    Liang G; Chai J; Ng HS; Tremlett H
    Mult Scler Relat Disord; 2020 Nov; 46():102566. PubMed ID: 33296968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-17
    Lückel C; Picard F; Raifer H; Campos Carrascosa L; Guralnik A; Zhang Y; Klein M; Bittner S; Steffen F; Moos S; Marini F; Gloury R; Kurschus FC; Chao YY; Bertrams W; Sexl V; Schmeck B; Bonetti L; Grusdat M; Lohoff M; Zielinski CE; Zipp F; Kallies A; Brenner D; Berger M; Bopp T; Tackenberg B; Huber M
    Nat Commun; 2019 Dec; 10(1):5722. PubMed ID: 31844089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
    Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
    Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis.
    Ravn J; Jensen HB; Kant M; Andersen PB; Góra MK; Sejbaek T
    Mult Scler Relat Disord; 2022 Nov; 67():104081. PubMed ID: 35944466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.
    Chen H; Assmann JC; Krenz A; Rahman M; Grimm M; Karsten CM; Köhl J; Offermanns S; Wettschureck N; Schwaninger M
    J Clin Invest; 2014 May; 124(5):2188-92. PubMed ID: 24691444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
    Zecca C; Antozzi CG; Torri Clerici V; Ferrazzini M; Mantegazza RE; Rossi S; Gobbi C
    Acta Neurol Scand; 2018 Jun; 137(6):623-625. PubMed ID: 29205270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimethyl fumarate treatment alters NK cell function in multiple sclerosis.
    Smith MD; Calabresi PA; Bhargava P
    Eur J Immunol; 2018 Feb; 48(2):380-383. PubMed ID: 29108094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
    Lucchini M; Prosperini L; Buscarinu MC; Centonze D; Conte A; Cortese A; Elia G; Fantozzi R; Ferraro E; Gasperini C; Ianniello A; Landi D; Marfia GA; Nociti V; Pozzilli C; Salvetti M; Tortorella C; Mirabella M
    J Neurol; 2021 Jun; 268(6):2238-2245. PubMed ID: 33496861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.
    Longbrake EE; Cantoni C; Chahin S; Cignarella F; Cross AH; Piccio L
    Mult Scler; 2018 May; 24(6):728-738. PubMed ID: 28480794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.